Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
48 hedge funds and large institutions have $101M invested in Kindred Biosciences, Inc. in 2017 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
94% more capital invested
Capital invested by funds: $52.4M → $101M (+$49.1M)
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
12% more funds holding
Funds holding: 43 → 48 (+5)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $96K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$15M |
| 2 |
AFS
Amtrust Financial Services
New York
|
+$1.57M |
| 3 |
Morgan Stanley
New York
|
+$1.42M |
| 4 |
Renaissance Technologies
New York
|
+$960K |
| 5 |
BlackRock
New York
|
+$619K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$6.04M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$416K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
-$289K |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$164K |
| 5 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$143K |
KIN Hedge Fund Activity: Q1 2017 in Review
48 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q1 2017, worth a combined $101M — up 94% from $52.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new KIN positions and 3 closed out — a net gain of 12 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was Park West Asset Management, adding an estimated $15M. The largest seller was Ariel Investments, cutting an estimated $6.04M.
- 48 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q1 2017, up from 43 in Q4 2016.
- Funds reported $101M of Kindred Biosciences, Inc. stock for Q1 2017, up 94% quarter-over-quarter.
- 15 funds opened new Kindred Biosciences, Inc. positions in Q1 2017 and 3 closed out, a net change of +12 holders.
- The largest Kindred Biosciences, Inc. buyer in Q1 2017 was Park West Asset Management, an estimated $15M added.
- The largest Kindred Biosciences, Inc. seller in Q1 2017 was Ariel Investments, an estimated $6.04M sold.
Based on aggregated 13F filings for Q1 2017.